The dose-finding portion of this Phase I clinical trial is designed to establish the maximum tolerated dose of IMGN853 and to define its dose-limiting toxicity (DLT). Patients with any type of cancer ...

Forty-six patients were enrolled. Adverse events were generally mild (≤ grade 2), with diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%) being the most commonly observed ...

ImmunoGen announced the first findings from company research aimed at optimizing the dosing of its IMGN853 product candidate. Based on findings in the first patients to receive IMGN853, ImmunoGen ...

ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target <0> For Investors:ImmunoGen, Inc.Carol Hausner, ...

ImmunoGen, Inc. IMGN, a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research ...

ImmunoGen, Inc. (NASDAQ: IMGN) shares were trading sharply higher by $5.92 (68 percent) at $14.90 in Monday's session. The catalyst for the rally to a new 52-week high is a report that its IMGN853 ...

<0> For Investors:ImmunoGen, Inc.Carol Hausner, 781-895-0600Executive Director, Investor Relations and Corporate CommunicationsorFor Media:The Yates NetworkBarbara Yates, 781-258-6153 </0> ImmunoGen, ...

First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers First clinical findings presented with ImmunoGen's folate receptor α (FRα)-targeting ...

First clinical findings presented with ImmunoGen's folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853. Preliminary evidence of activity seen in dose-finding portion of trial.

First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers The dose-finding portion of this Phase I clinical trial is designed to establish the ...